The latest price target for Avid Bioservices (NASDAQ:CDMO) was reported by RBC Capital on September 10, 2024. The analyst firm set a price target for $12.00 expecting CDMO to rise to within 12 months (a possible 7.91% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Avid Bioservices (NASDAQ:CDMO) was provided by RBC Capital, and Avid Bioservices maintained their outperform rating.

The last upgrade for Avid Bioservices Inc happened on March 14, 2023 when Keybanc raised their price target to $20. Keybanc previously had a sector weight for Avid Bioservices Inc.

The last downgrade for Avid Bioservices Inc happened on December 8, 2021 when Keybanc changed their price target from N/A to N/A for Avid Bioservices Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avid Bioservices, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avid Bioservices was filed on September 10, 2024 so you should expect the next rating to be made available sometime around September 10, 2025.

While ratings are subjective and will change, the latest Avid Bioservices (CDMO) rating was a maintained with a price target of $8.00 to $12.00. The current price Avid Bioservices (CDMO) is trading at is $11.12, which is within the analyst’s predicted range.